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To obtain the amino acid sequence at the thiol ester site in duck ovostatin for comparisons with other pro- 
teins, the native ovostatin was labeled with r4CHsNH2 at the reactive thiol ester site. The modified protein 
was reduced, carboxymethylated, and digested with trypsin. 14C-labeled peptides isolated by gel filtration 
with Sephadex G-50, ion-exchange chromatography on DEAE-cellulose and HPLC were subjected to au- 
tomated sequence analysis, and the stretch of 32 amino acid residues containing the r4CH3NHz-binding site 
were determined. A comparison of this sequence with the corresponding sequences in al-macroglobulin, and 
complement components C3 and C4 revealed 72, 31 and 34% homology, respectively. The results indicate 
that ovostatin is a close relative to plasma cr-macroglobulins and may share a common ancestor with C3 
and C4. 
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1. INTRODUCTION 
Ovostatin (ovomacroglobulin) is a tetrameric 
glycoprotein proteinase inhibitor synthesized 
specifically in avian [l-3] and reptilian [4] oviduct. 
The native molecule (MI 780000) consists of four 
identical subunits (M, 195000) which are linked in 
pairs by disulfide bonds [3]. The binding of a pro- 
teinase to ovostatin is initiated by proteolysis of a 
specific region of a subunit. This event triggers a 
conformational change in ovostatin resulting in the 
entrapment of the enzyme molecule without block- 
ing the active site [5]. Thus, inhibition of pro- 
teinases is observed only when high-M, substrates 
are used. These observations indicate that the 
quaternary structure and the mechanism of pro- 
teinase inhibition by ovostatin are similar to those 
of the plasma glycoprotein, cuz-macroglobulin 
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&M) [5,6]. Indeed, the NHz-terminal sequences 
of ovostatin and azM are sufficiently similar 
(about 36% identical in their first 14 residues) to 
suggest that the structural genes for ovostatin and 
azM may have evolved from a common ancestor 
[3,7,8]. In spite of their similarities, evolutionary 
divergence has resulted in differences in 
specificities and chemical properties. Chicken 
ovostatin inhibits only metalloproteinases 
stoichiometrically [5] and duck ovostatin inhibits 
metalloproteinases and serine proteinases but not 
cysteine proteinases [7], whereas ~YIM can bind and 
inhibit glmost all endopeptidases from four major 
classes of proteinases [6]. In addition, the most 
striking difference found between chicken 
ovostatin and CWM is that chicken ovostatin lacks 
a reactive thiol ester [5]. As a result, chicken 
ovostatin, unlike &2M, does not form a covalent 
linkage with the entrapped proteinase. Although 
the example of chicken ovostatin demonstrates 
that the thiol ester moiety is not essential for pro- 
teinases inhibition by this family of proteins, thiol 
esters have been found in all cu-macroglobulins in 
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plasma from various species reported so far 
[3,9-131. 
More recently, however, we have reported that 
such a thiol ester is present in duck ovostatin [7]. 
Thiol esters have also been found in complement 
components C3 [14-161 and C4 [17,18], and 
similarities in sequence around this region in a2M 
and C3 and C4 have suggested that they share a 
common evolutionary origin [ 19,201. 
In order to locate an internal thiol ester in duck 
ovostatin and to examine its structural relationship 
with a2M, C3 and C4, we have sequenced 32 amino 
acid residues around the thiol ester site in duck 
ovostatin. The sequence analysis displays a high 
degree of similarity with the corresponding se- 
quences of cv2M and to a lesser extent with those of 
C3 and C4. The results further support the 
hypothesis that parts of the structural genes for 
ovostatin, (YzM, C3 and C4, have arisen from a 
common ancestor. 
2. MATERIALS AND METHODS 
2.1. Materials 
Duck ovostatin was purified as described [7]. 
14CH3NH2 - HCl (spec. act. 56 mCi/mmol) was 
from Amersham. CHsNHz.HCl, dithiothreitol, 
iodoacetic acid and TPCK-treated trypsin were 
from Sigma. Sephadex G-50 (superfine) and DE-52 
were from Pharmacia and Whatman, respectively. 
2.2. 14CH3NH~ labeling of duck ovostatin 
Labeling of duck ovostatin with i4CH3NH2 was 
first carried out by reacting 225 ~1 ovostatin 
(10.6 mg/ml) with 90~1 of 175 mM 14CHsNHz 
(10 mCi/ml) in 0.1 M boric acid/NaOH, pH 8.6, 
containing 0.2 M NaCl. The final concentration of 
14CHsNH2 was 50 mM, conditions under which 
the labeling reaction proceeds efficiently. After a 
4 h reaction at 37”C, 1 ml duck ovostatin 
(10.6 mg/ml) was added to the mixture and it was 
further incubated at 37°C for 4 h. The sample was 
then mixed with 24 ml duck ovostatin 
(10.6 mg/ml) in 0.1 M boric acid/NaOH, pH 8.6, 
containing 0.2 M NaCl, incubated at 37°C for 1 h. 
The sample was then treated with 0.2 M CH3NHz 
for 16 h at room temperature in order to obtain a 
chemically uniform product. 
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2.3. Tryptic digestion of duck ovostatin 
14CHsNH2-labeled ovostatin was dialyzed 
against 50 mM NI&HCO3, lyophilized, dissolved 
in 35 ml of 0.1 M Tris-HCl, pH 8.6/8 M urea, 
reduced with 10 mM dithiothreitol at 37’C for 4 h 
and alkylated with 30 mM iodoacetic acid. Re- 
duced, carboxymethylated 14CH3NH2-labeled 
ovostatin was dialyzed against 50 mM NH4HCO3, 
lyophilized, and digested with 5 mg TPCK-trypsin 
in 20 ml of 50 mM NH4HCOs containing 1 mM 
CaCl2 for 2 h at 37’C, then with an additional 
5 mg TPCK-trypsin for 2 h. Insoluble peptides 
generated were separated by centrifugation. More 
than 90% of the radioactivity was recovered in the 
supernatant. The tryptic fragments containing 
radioactivity were purified by a series of 
chromatographic techniques (see section 3). CNBr 
cleavage was carried out with a 2% (w/v) solution 
of CNBr in 70% formic acid for 18 h at 20°C. 
2.4. Amino acid analysis 
Peptides were hydrolyzed with 6 N HCl at 
110°C for 24 h and amino acid compositions 
determined by conversion to PTC derivatives and 
analysis by HPLC. Hydrolysis and conversion was 
carried out with a Waters Pica Tag workstation, 
and analysis with a Waters Pica Tag HPLC col- 
umn, following the procedures suggested by the 
manufacturer. 
2.5. Sequence analysis 
Automatic sequence analyses were performed 
with an Applied Biosystems 470A protein se- 
quencer using standard programs. PTH-amino 
acids were identified and quantified by reverse- 
phase HPLC using a Hewlett Packard 1090 liquid 
chromatograph with an Applied Biosystems nar- 
row bore (2.1 x 220 mm) PTH-Cl8 cartridge 
system. HPLC solvents were supplied by Applied 
Biosystems, and elution was carried out following 
their recommendations. 
3. RESULTS AND DISCUSSION 
3.1. Isolation of “CH3NN2-iabeled peptides 
14C-labeled peptides generated by TPCK-treated 
trypsin digestion were separated first with a col- 
umn of Sephadex G-50 superfine (4.5 x 55 cm), 
equilibrated and eluted with 50 mM NH4HCOs. 
Three radioactive peaks were detected but only the 
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Fig. 1. Separation of two 14C-labeled peptides by reverse- 
phase HPLC. 14C-labeled peptides obtained after DE-52 
chromatography were dissolved in 2 ml of 6 M 
guanidine - HCl/lS% formic acid, and 400 ,ul of the 
sample was applied to a reverse-phase C-18 column 
(Vydac) equilibrated with 0.1% trifluoroacetic acid. The 
peptides were eluted with a linear gradient at a flow rate 
of 1 ml/min. Each peak of A212 was collected and 
measured for radioactivity. Peaks A and B had 40 and 
60% of the total radioactivity, respectively. 
fractions containing the major peak were pooled, 
lyophilized, and subjected to further purification. 
The lyophilized material from the Sephadex G-50 
column was dissolved in 10 mM N&HCOs and 
applied to a column of DE-52 (2 x 20 cm) 
equilibrated with the same solvent. The 14C-labeled 
peptides bound to DE-52 and were eluted with a 
gradient of NH4HC03. The majority of the 14C 
label appeared in one major peak. The pool from 
DE-52 was lyophilized and dissolved in 2 ml of 
6 M guanidine -HC1/15% formic acid. The frac- 
tion was further purified by HPLC (Bio Rad 
MAPS system) with a reverse-phase column 
(Vydac Cl8 protein and peptide column) using a 
gradient of 25-609’0 acetonitrile containing 0.1% 
trifluoroacetic acid (fig.1). The 14C label was 
found in two peaks (peak A with 40% and peak B 
with 60% of the total radioactivity). 
Table 1 
Sequence of r4CHsNH2-labeled peptides of duck ovostatin 
Cycle Peptide A 
Residue Yield 
Peptide B 
Residue Yield 
Peptide A-3 
Residue Yield cpm 
1 Ser 112 
2 Val 318 
3 Val 490 
4 GlY 270 
5 Asp 203 
6 Be 324 
7 Met 230 
8 GfY 202 
9 Thr 68 
10 Ser 65 
11 Met 238 
12 Gin 195 
13 Asn 156 
14 Leu 290 
15 His 62 
16 Gin 124 
17 Leu 177 
18 Leu 246 
19 Gln 104 
20 Met 108 
21 Pro 99 
22 Phe 104 
23 Gly 81 
24 Cm-Cys 32 
Ala 1195 
Ser 380 
Phe 435 
Ser 190 
Val 490 
Val 385 
GUY 260 
Asp 180 
Pro 232 64 
Phe 234 40 
Gly 173 262 
Cm-Cys 98 202 
Gly 148 240 
Glu 127 208 
“CHrNH-Glu 103 1375 
Asn ‘46 1050 
Met N.D. 180 
Yields at each cycle are given in pmol. N.D., not determined 
85 
Volume 222, number 1 FEBS LETTERS September 1987 
Table 2 
Amino acid composition of peptides A, B, and A-3 
Peptide A Peptide B Peptide A-3 
Asp 3.44 (3) 6.13 (6) 0.88 (1) 
GlU 5.90 (5) 9.80 (10) 2.02 (2) 
Cm-Cys N.I. (1) 1.07 (1) 0.72 (1) 
Ser 2.5 (3) 5.4 (5) 
GlY 4.07 (4) 6.9 (7) 2.30 (2) 
His 0.97 (1) 1.6 (2) 
Arg 
Thr 1.7 (1) 2.55 (3) 
Ala 2.28 (2) 
Pro 0.87 (1) 1.75 (2) 0.89 (1) 
Tyr N.D. N.D. 
Val 2.32 (2) 3.43 (3) 
Met 3.9 (4) 4.15 (4) N.I. (1) 
Be 1.28 (1) 2.08 (2) 
Leu 2.74 (3) 5.45 (5) 
Phe 1.47 (2) 3.70 (4) 0.94 (1) 
LYS 0.60 (1) 
N.I., not identified; N.D., not determined 
3.2. Sequence analyses of peptide A andpeptide B 
From four separate runs of HPLC as shown in 
fig. 1, the pools of peptides A and B were combined 
separately, dried under vacuum, and one-fifth of 
each peptide was used for analyses of sequence 
(table 1) and amino acid composition (table 2). The 
sequence obtained for the first 24 residues of pep- 
tide A appeared to correspond to residues 926-949 
in human ~zM [8]. Cm-Cys identified in cycle 24 
was possibly the Cys residue which is generated 
from the cleavage of the thiol ester bond between 
Cys and Glx analogously to UZM [21-231. One SH 
group is generated from each ovostatin subunit 
after treating the native duck ovostatin with 
CH3NH2 [7]. Peptide B showed an identical se- 
quence to that of peptide A, but with three addi- 
tional residues (Ala-Ser-Phe) at the amino-ter- 
minus of peptide A (table 1). Peptide B was pro- 
bably generated by normal tryptic cleavage of duck 
ovostatin since in wM, the residue preceding this 
region is Arg [8], and peptide A was generated by 
cleavage at the Phe-Ser bond as a result of 
residual chymotryptic activity in the trypsin 
preparation. Indeed, the amino acid composition 
of peptide B revealed one residue of Lys, and pep- 
tide A appeared to be considerably shorter than 
peptide B (table 2). 
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Fig.2. Separation of CNBr fragments of peptide A by 
reverse-phase HPLC. Peptide A was reacted with 200 ,~l 
of a 2% (w/v) solution of CNBr in 70% formic acid at 
23°C for 18 h. After drying in vacua over NaOH pellets, 
the products were dissolved in 6 M guanidine. HCl and 
applied to a reverse-phase Cl8 column (Vydac) attached 
to an HPLC system (Bio-Rad MAPS). The peptides 
were eluted with the linear gradient of acetonitrile at a 
flow rate of 1 ml/min. Each peak of A212 was collected 
and measured for radioactivity. i4C label was found in 
peak A-3. 
To determine a more extended sequence around 
the thiol ester site of duck ovostatin, the remaining 
peptide A was cleaved with CNBr and the 
fragments generated were separated by HPLC with 
a reverse-phase C-18 column (fig.2). 14C label was 
only found in peptide A-3. Sequence analysis of 
A-3 showed that the peptide was generated by 
cleavage of the Met-Pro between residues 20 and 
21 of peptide A (table 1). After each Edman 
degradation cycle of peptide A-3, the amount of 
14C label recovered in the PTH derivative was 
measured to identify the site of 14CH3NH2 incor- 
poration. Radioactivity was recovered in cycle 7 
and to a lesser extent in cycle 8 (table l), indicating 
that 14CH3NH2 was covalently linked to residue 7 
of peptide A-3. Identification of this residue as Glx 
was deduced from the amino acid composition of 
peptide A-3 (table 2) and by the presence of a PTH 
derivative that eluted at a distinct position from 
those of normal amino acids together with some 
PTH-Glu resulting from the cleavage of the 
methylamine moiety during the conversion of 
anilinothiazoline to a PTH derivative. 
3.3. Comparison of the sequences around the thiol 
ester sites of ovostatin, a&T, C3 and C4 
At present, it appears that reactive inter-chain @- 
cysteinyl-y-glutamyl thiol esters are uniquely 
found in complement components C3 and C4 and 
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Fig.3. Sequence around the thiol ester sites of duck ovostatin, human [8] and rat [32] a2M, human [33] and mouse [34] 
C3 and human [35] and mouse [36] C4. The box denotes residues identical to those in duck ovostatin. The numbers 
correspond to the residues in human (YZM [8]. Residues indicated by asterisks form thiol ester bonds in the native 
molecules. 
the members of the CQM family including pregnan- 
cy zone protein [24], a 360-kDa a-macroglobulin 
homologue from fish plasma [ 131, murinoglobulin 
[25], rat plasma cur-inhibitor III [26] and @2M-like 
inhibitor from horseshoe crab [27]. 
Although the functions of the complement fac- 
tors and proteinase inhibitors are different, the 
presence of a thiol ester in the proteins is reflected 
in some common functional properties [19,28]: (i) 
the proteinase-binding capacity of most cy- 
macroglobulins and the hemolytic activities of C3 
and C4 are lost upon incubation with small 
nucleophilic amines, where these nucleophiles 
react to form covalent bonds with activated 
residues; (ii) upon reacting with proteinases, thiol 
ester groups in a2M become activated and allow 
(YZM to bind to an entrapped proteinase covalently 
while C3 and C4 are coupled to either IgG or to 
erythrocyte membranes upon activation; (iii) on 
reacting with either proteinases or nucleophilic 
amines, free SH groups are generated; and (iv) 
during heat denaturation characteristic autolytic 
fragments are produced. We have previously 
reported that the above effects are not observed 
with chicken ovostatin because it lacks a thiol ester 
[5]. The studies reported here demonstrate at the 
sequence level that in duck ovostatin the thiol ester 
is conserved, indicating that ovostatins are close 
relatives of the a2M group. In the comparison of 
the 32 residues around the methylamine-labeling 
site of duck ovostatin with the equivalent region of 
human a2M, C3 and C4 (fig.3), 23 residues were 
found to be identical with those of human cvzM 
(72% homology) but only 10 and 11 residues iden- 
tical to those of C3 (31% homology) and C4 (34% 
homology). Since the sizes of the autolytic 
fragments (MI 123 000 and Mr 60000) are similar to 
those produced from a~2M [7,30], and the sequence 
around the thiol ester displays strong homology 
between the two molecules, the thiol ester group in 
duck ovostatin appears to be located at an 
equivalent site in the sequence to that of cv2M 
(about 2/3 away from the NHz-terminus). 
CHsNHz sensitivity has been also reported for 
crocodile ovostatin [29]. 
The presence of an cuzM-like molecule contain- 
ing a CHsNHz-sensitive site in horseshoe crab in- 
dicates that the proteins of this family arose at 
least 550 million years ago [27,31] and have been 
conserved during the course of evolution. Further- 
more, the sequence around this region is highly 
conserved even in C3 and C4 (fig.3). This may 
reflect the requirement of a specific sequence and 
conformation for the formation of the thiol ester 
group during protein folding although the func- 
tions of these proteins are different from those of 
the proteins in the cvzM family. It is, however, 
enigmatic that chicken ovostatin lacks a thiol ester 
in spite of its close structural similarity to the duck 
protein as reflected in their identical amino- 
terminal 1Cresidue sequences [7] and their im- 
munological partial cross-reactivity. In contrast, 
only 36% homology is found in the NHz-termini of 
ovostatin and CY~M [7] and they are immunological- 
ly distinct [1,3]. Yet, there is 72% homology be- 
tween duck ovostatin and human cv2M in the region 
containing the thiol ester, and all proteins in the 
cv2M family described in the literature, except 
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chicken ovostatin, have CHsNH;?-sensitive sites, 
presumably reflecting the presence of thiol esters. 
To understand the evolutionary and functional 
relationship of this family of proteins, we are cur- 
rently investigating the sequence in chicken 
ovostatin which corresponds to the thiol ester sites 
of other members of this family using molecular 
cloning techniques. 
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